Department of Nephrology, Unidade Local de Saúde de Santo António (ULSdSA), Porto, Portugal.
UMIB - Unit for Multidisciplinary Research in Biomedicine, ICBAS - School of Medicine and Biomedical Sciences, University of Porto, Porto, Portugal.
Transpl Int. 2024 Aug 26;37:13356. doi: 10.3389/ti.2024.13356. eCollection 2024.
A living donor (LD) kidney transplant is the best treatment for kidney failure, but LDs safety is paramount. We sought to evaluate our LDs cohort's longitudinal changes in estimated glomerular filtration rate (eGFR). We retrospectively studied 320 LDs submitted to nephrectomy between 1998 and 2020. The primary outcome was the eGFR change until 15 years (y) post-donation. Subgroup analysis considered distinct donor characteristics and kidney function reduction rate (%KFRR) post-donation [-(eGFR-eGFR)/eGFR*100]. Donors had a mean age of 47.3 ± 10.5 years, 71% female. Overall, LDs presented an average eGFR change 6 M onward of +0.35 mL/min/1.73 m/year. The period with the highest increase was 6 M-2 Y, with a mean eGFR change of +0.85L/min/1.73 m/year. Recovery plateaued at 10 years. Normal weight donors presented significantly better recovery of eGFR +0.59 mL/min/1.73 m/year, compared to obese donors -0.18L/min/1.73 m/year ( = 0.020). Noteworthy, these results only hold for the first 5 years. The subgroup with a lower KFRR (<26.2%) had a significantly higher decrease in eGFR overall of -0.21 mL/min/1.73 m/year compared to the groups with higher KFRR ( < 0.001). These differences only hold for 6 M-2 Y. Moreover, an eGFR<50 mL/min/1.73 m was a rare event, with ≤5% prevalence in the 2-15 Y span, correlating with eGFR pre-donation. Our data show that eGFR recovery is significant and may last until 10 years post-donation. However, some subgroups presented more ominous kidney function trajectories.
活体供肾移植是治疗肾衰竭的最佳方法,但供者安全至关重要。我们旨在评估我们的活体供者队列在估算肾小球滤过率(eGFR)方面的纵向变化。我们回顾性研究了 1998 年至 2020 年间接受肾切除术的 320 名活体供者。主要结局是供者在捐赠后 15 年内 eGFR 的变化。亚组分析考虑了不同的供者特征和捐赠后 eGFR 下降率(%KFRR)[-(eGFR-eGFR)/eGFR*100]。供者的平均年龄为 47.3±10.5 岁,71%为女性。总体而言,供者在 6 个月后 eGFR 呈持续增加趋势,平均每年增加 0.35mL/min/1.73m。增加幅度最高的时期为 6 个月至 2 年,平均 eGFR 每年增加 0.85L/min/1.73m。10 年后,eGFR 恢复趋于平稳。与肥胖供者(-0.18L/min/1.73m/年,=0.020)相比,体重正常的供者 eGFR 恢复明显更好,为+0.59mL/min/1.73m/年。值得注意的是,这些结果仅在前 5 年内成立。KFRR 较低(<26.2%)的亚组在整个 eGFR 下降方面显著更高,为-0.21mL/min/1.73m/年,而 KFRR 较高的亚组(<0.001)则相反。这些差异仅在前 6 个月至 2 年内成立。此外,eGFR<50mL/min/1.73m 是一种罕见事件,在 2-15 年内的患病率≤5%,与 eGFR 供者前值相关。我们的数据表明,eGFR 的恢复是显著的,可能持续到捐赠后 10 年。然而,一些亚组的肾功能轨迹更具威胁性。